Development of a vaccine for invasive aspergillosis

Clinical Infectious Diseases

Volumn 38, Issue 8, 2004, Pages 1137-1138

  Sheppard, Donald C ^a,c   Edwards Jr , John E ^a,b  

^a St John's Cardiovascular Research Center   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; ASPERGILLUS VACCINE; FUNGUS VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOSUPPRESSIVE AGENT; UNCLASSIFIED DRUG; FUNGUS ANTIGEN;

ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; BONE MARROW TRANSPLANTATION; CANDIDA ALBICANS; DISEASE COURSE; DRUG EFFICACY; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; MACROPHAGE; NONHUMAN; NOTE; PRIORITY JOURNAL; SIDE EFFECT; T LYMPHOCYTE; ANIMAL; ASPERGILLUS; DISEASE MODEL; IMMUNOLOGY; LUNG MYCOSIS; MOUSE;

ANIMALS; ANTIGENS, FUNGAL; ASPERGILLOSIS; ASPERGILLUS; DISEASE MODELS, ANIMAL; FUNGAL VACCINES; IMMUNOCOMPROMISED HOST; LUNG DISEASES, FUNGAL; MICE;

EID: 2342458470     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/382890     Document Type: Note

References (19)

1. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23: 608-15.
2. Denning DW, Marinus A, Cohen J, et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect 1998; 37:173-80.
3. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15.
4. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33:23-32.
5. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909-17.
6. Stevens DA. Vaccinate against aspergillosis! A call to arms of the immune system. Clin Infect Dis 2004; 38:1131-6 (in this issue).
7. Holding KJ, Dworkin MS, Wan PC, et al. Aspergillosis among people infected with human immunodeficiency virus: incidence and survival: Adult and Adolescent Spectrum of HIV Disease Project. Clin Infect Dis 2000; 31: 1253-7.
8. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358-66.
9. De Rosa FG, Shaz D, Campagna AC, Dellaripa PE, Khettry U, Craven DE. Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case? Infect Control Hosp Epidemiol 2003; 24:477-82.
10. Marty FM, Lee SJ, Fahey MM, et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 2003; 102:2768-76.
11. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001; 344: 1099-100.
12. Cenci E, Mencacci A, Bacci A, Bistoni F, Kurup VP, Romani L. T cell vaccination in mice with invasive pulmonary aspergillosis. J Immunol 2000; 165:381-8.
13. Ito JI, Lyons JM. Vaccination of corticosteroid immunosuppressed mice against invasive pulmonary aspergillosis. J Infect Dis 2002; 186: 869-71.
14. Bozza S, Gaziano R, Lipford GB, et al. Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. Microbes Infect 2002; 4:1281-90.
15. Clemons KV, Stevens DA. Overview of host defense mechanisms in systemic mycoses and the basis for immunotherapy. Semin Respir Infect 2001; 16:60-6.
16. de Repentigny L, Petitbois S, Boushira M, et al. Acquired immunity in experimental murine aspergillosis is mediated by macrophages. Infect Immun 1993; 61:3791-802.
17. Moragues MD, Omaetxebarria MJ, Elguezabal N, et al. A monoclonal antibody directed against a Candida albicans cell wall manno-protein exerts three anti-C. albicans activities. Infect Immun 2003; 71:5273-9.
18. Cenci E, Mencacci A, Spreca A, et al. Protection of killer antiidiotypic antibodies against early invasive aspergillosis in a murine model of allogeneic T-cell-depleted bone marrow transplantation. Infect Immun 2002; 70: 2375-82.
19. Bozza S, Perruccio K, Montagnoli C, et al. A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood 2003; 102:3807-14.